Literature DB >> 12107613

Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale.

L de Haan1, M Weisfelt, P M A J Dingemans, D H Linszen, L Wouters.   

Abstract

RATIONALE: Subjective experience of antipsychotic drugs is relevant for medication compliance and quality of life. There is, however, sparse knowledge about the assessment of subjective experience.
OBJECTIVES: To examine the internal consistency, test-retest reliability, sensitivity to medication change and concurrent validity of two test instruments: the Subjective Well-Being Under Neuroleptics (SWN) and the Subjective Deficit Syndrome Scale (SDSS).
METHODS: Both instruments were used at admission and after 6 weeks of medication stabilization in 105 consecutively admitted patients diagnosed with DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edn) diagnoses of recent-onset schizophrenia, schizophreniform disorder or schizoaffective disorder.
RESULTS: Almost all patients were capable of reproducing their subjective experience in a consistent way both before and after medication stabilization. The internal consistency of both instruments was high. The test-retest reliability was high if medication was not changed, especially for the SWN. The SWN was sensitive for changes in medication and dosage. The short form of the SWN (SWN-20 items) had comparable psychometric qualities to the original instrument (SWN-38 items). The concurrent validity of the SWN and the SDSS was good, indicating that both tests measure the same concept.
CONCLUSIONS: The assessment of subjective experience with the SWN (both versions) may be used in evaluating differential effects of anti-psychotics and dose on subjective well-being.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107613     DOI: 10.1007/s00213-002-1054-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  The Scandinavian Solutions for Wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders.

Authors:  Vibeke Porsdal; Catherine Beal; Ole Kristian Kleivenes; Egil W Martinsen; Eva Lindström; Harriet Nilsson; Pär Svanborg
Journal:  BMC Psychiatry       Date:  2010-06-10       Impact factor: 3.630

2.  Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis.

Authors:  Shaun M Eack; Christina E Newhill
Journal:  Schizophr Bull       Date:  2007-01-04       Impact factor: 9.306

3.  Constructing an Index for the Subjective Well-being Under Neuroleptics scale (SWN), short form: applying structural equation modeling for testing reliability and validity of the index.

Authors:  Peter Schmidt; Johannes Clouth; Lars Haggenmüller; Dieter Naber; Ursula Reitberger
Journal:  Qual Life Res       Date:  2006-09-26       Impact factor: 4.147

4.  Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study.

Authors:  Alkomiet Hasan; Claus Wolff-Menzler; Sebastian Pfeiffer; Peter Falkai; Elif Weidinger; Andrea Jobst; Imke Hoell; Berend Malchow; Peyman Yeganeh-Doost; Wolfgang Strube; Silke Quast; Norbert Müller; Thomas Wobrock
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-07-26       Impact factor: 5.270

Review 5.  Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life.

Authors:  Martin Lambert; Dieter Naber
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Developing a measure of medication-related quality of life for people with polypharmacy.

Authors:  Hsu-Min Tseng; Chia-Hui Lee; Yin-Jen Chen; Hsiang-Hao Hsu; Li-Yueh Huang; Jing-Long Huang
Journal:  Qual Life Res       Date:  2015-11-19       Impact factor: 4.147

Review 7.  The impact of subjective well-being under neuroleptic treatment on compliance and remission.

Authors:  Walter de Millas; Martin Lambert; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

Review 8.  Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.

Authors:  Henk S Temmingh; Taryn Williams; Nandi Siegfried; Dan J Stein
Journal:  Cochrane Database Syst Rev       Date:  2018-01-22

9.  Preliminary data concerning the reliability and psychometric properties of the Greek translation of the 20-item Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-20).

Authors:  Melina Siamouli; Katerina Moutou; Eleonora Pantoula; Stamatia Magiria; Irini Chatzivasileiou; Konstantinos Arapidis; Achileas Chatzivasileiou; Simeon Deres; Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2009-01-21       Impact factor: 3.455

10.  AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures.

Authors:  Erik Boot; Jan Booij; Gregor Hasler; Janneke R Zinkstok; Lieuwe de Haan; Don H Linszen; Thérèse A van Amelsvoort
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-19       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.